Navigation Links
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that the company will present the results of several preclinical studies at the 54th annual meeting of the Society of Nuclear Medicine (SNM) in Washington, D.C. The presentations include data on Azedra(TM) (Ultratrace (131)I-MIBG), the company's clinical-stage, targeted radiotherapeutic candidate for the treatment of malignant neuroendocrine tumors; Zemiva, its lead molecular imaging pharmaceutical for imaging cardiac ischemia; and MIP-190, its molecular imaging pharmaceutical candidate that targets angiotensin converting enzyme for the detection of heart failure and vascular inflammatory disease. Data on the company's radiolabeled small molecule molecular imaging pharmaceutical, MIP-1072, for the detection and staging of prostate cancer, were presented on June 3rd. -0-
Abstract Title: Formulation comparisons and pharmacokinetics of high

                specific activity Ultratrace 131I-Iobenguane (mIBG)

                for therapy


Authors:        J. F. Kronauge(a1), J. A. Barrett(1), J. Qi(1),

                H. Mok(1), D. H. Hunter(2), C. Bensimon(4),

                S. Oelsner(4), J. P. Norenberg(3), T. Anderson(3),

                S. Gallo(1), S. M. Hiller(1), J. Joyal(1),

                N. S. Lee(1) and J. W. Babich(1);

                1. Molecular Insight Pharmaceuticals, Inc., Cambridge,

                Massachusetts; 2. University of Western Ontario,

                London, Ontario, Canada; 3. University of New Mexico,

                Albuquerque, New Mexico and 4. MDS Nordion, Kanata,

                Ontario, Canada.


Reference #:    335357


Publication No.: 1316 - Scientific Poster Session


Poster Section:  Dosimetry/Radiobiology Posters


Session Info:   "Meet the Author" II: Neurosciences, General Clinical

                Specialties, and Radiopharmaceutical Chemistry Posters

                Monday, June 4

    
            3:15 PM- 4:00 PM

                Hall E


-0-

Abstract Title: A comparison of Iodine-123 and Technetium-99m assays

                using dose calibrators


Authors:        D. L. Yokell(a), J. F. Kronauge, C. S. Kao and J. W.

                Babich; Development, Molecular Insight

                Pharmaceuticals, Inc., Cambridge, Massachusetts.


Reference #:    335015


Publication No.: 1835 - Scientific Poster Session


Poster Section: Instrumentation Posters


Session Info:   "Meet the Author" IV: Instrumentation & Data Analysis

                Posters

                Tuesday, June 5

                1:15 PM - 2:00 PM

                Hall E

-0-

Abstract Title: Synthesis and evaluation of a series of M(CO)3+

                (M=Tc,Re) lisinopril complexes for imaging angiotensin

                converting enzyme (ACE)


Authors:        F. J. Femia(a1), K. P. Maresca(1), S. M. Hillier(1),

                C. N. Zimmerman(1), J. L. Joyal(1), J. A. Barrett(1),

                T. Coleman(2), O. Aras(2), C. A. Foss(3),

                M. G. Pomper(3), V. Dilsizian(2), W. C. Eckelman(1)

                and J. W. Babich(1); 1. Molecular Insight

                Pharmaceuticals, Inc., Cambridge, Massachusetts;

                2. Nuclear Medicine, University of Maryland,

                Baltimore, Maryland and 3. Radiology, Johns Hopkins

                Medical Institutions, Baltimore, Maryland.


Reference #:    331898


Publication No.: 613 - Scientific Paper Session (Oral)


Session Info:   New Chemistry-Other II

                Wednesday, June 6

                9:45 AM - 11:15 AM

                Room 145A

On June 3rd, researchers at Molecular Insight also presented preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. MIP-1072 is designed to target prostate specific membrane antigen (PSMA), a protein found predominantly on prostate tumor cells. The paper, "Molecular Targeting of Prostate Cancer with Small Molecular Inhibitors of Prostate Specific Membrane Antigen," was honored by SNM with the 2007 Berson-Yalow Award for most original scientific abstract.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical result s or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications
& Investor Relations


'"/>




Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the Cowen and Company 37 ... Marriott Copley Place on Tuesday, March 7, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
Breaking Medicine News(10 mins):